NeuroSigma Responds to Substantial Interest Generated by NPR Story on Promising Epilepsy Clinical Trial

Bio-Medicine.Org

LOS ANGELES, Aug. 4, 2011 /PRNewswire/ -- NeuroSigma, Inc., a Los Angeles-based medical device company, today provided an update in response to substantial interest and inquiries generated by a National Public Radio (NPR) news story which aired July 27, 2011 on the use of non-invasive Trigeminal Nerve Stimulation (TNS) for the treatment of drug-resistant epilepsy.

(http://www.npr.org/2011/07/27/138619259/new-device-reduces-seizures-no-surgery-required [1]).

Dr. Christopher DeGiorgio, a neurologist at the University of California, Los Angeles (UCLA) and scientific advisor to NeuroSigma, who was interviewed in the NPR story, pioneered the development of TNS for epilepsy. NeuroSigma is the exclusive licensee of UCLA's TNS intellectual property.

NeuroSigma is now planning a Phase III pivotal trial for its external TNS (eTNS™) system. Earlier this year, Dr. DeGiorgio delivered results of the 50-subject Phase II double-blind clinical trial to the Antiepileptic Drug Trials XI Conference in Miami, Florida. The results compared favorably with those of pharmaceuticals and surgically-implanted devices. (http://www.prnewswire.com/news-releases/positive-results-reported-for-phase-ii-randomized-double-blind-clinical-trial-for-the-treatment-of-drug-resistant-epilepsy-using-external-trigeminal-nerve-stimulation-etns---the-usb-port-to-the-brain-120917294.html [2])

The study found that subjects receiving NeuroSigma's active eTNS™ treatment experienced a significant improvement in seizure reduction, while those randomized to receive the control condition ("sham"
'/>"/>

SOURCE [3]

Source URL (retrieved on *03/12/2014 - 3:04am*):
http://www.mdtmag.com/news/2011/08/neurosigma-responds-substantial-interest-generated-npr-story-promising-epilepsy-clinical-trial?qt-most_popular=0

Links:
[1] http://www.npr.org/2011/07/27/138619259/new-device-reduces-seizures-no-surgery-required
[2] http://www.prnewswire.com/news-releases/positive-results-reported-for-phase-ii-

randomized-double-blind-clinical-trial-for-the-treatment-of-drug-resistant-epilepsy-using-external-trigeminal-nerve-stimulation-etns---the-usb-port-to-the-brain-120917294.html
[3] http://www.bio-medicine.org/medicine-technology-1/NeuroSigma-Responds-to-Substantial-Interest-Generated-by-NPR-Story-on-Promising-Epilepsy-Clinical-Trial-19311-1/